Xiao Huang:DOORM, how has the first AI drug performed in the market? Why are its revenue and profits poor?
DOORM:The first AI drug was approved in 2022, but its market performance has been poor for several reasons. Firstly, this drug is only an in-hospital prescription and cannot be taken home, limiting its market coverage. Secondly, its application range is narrow, mainly for treating schizophrenia and bipolar disorder, which have relatively small market sizes. Additionally, although AI has shown great potential in drug development, its real market application still requires time and more clinical validation.
发表回复
要发表评论，您必须先登录。